Clinical Trials Browser

Phase 1/2 × Leukemia, Myeloid, Acute × atezolizumab × Clear all

NCT03730012 2024-11-29

A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)

Phase 1/2 Completed

11 enrolled 18 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03154827 2024-09-05

Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)

Phase 1/2 Terminated

1 enrolled 6 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute